• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Applying Data Science Principles to FDA’s PreCert Program: Some Scary Stuff

Share:

November 5, 2019

Drugs or products approval concept. Rubber stamp with the text FDA approved over white background. 3D illustration

Epstein Becker & Green’s Bradley Merrill Thompson explains why the FDA PreCert Program’s built-in subjectivity and bias toward established entities should worry the healthcare and medical technology industry.

Let’s say I could show you, through reliable data that is statistically significant, that children from wealthy families on average make much better employees in very meaningful ways. Do you think companies ought to adopt policies — perhaps embedded in algorithms — that favor hiring from wealthy families? That sounds pretty un-American.

So why is everyone so excited about creating an easier pathway through FDA for projects that come from certain incumbent companies that have a pedigree demonstrating that they have been more successful in the past? In a nutshell, that’s FDA’s PreCert Program presently under development.

Throughout FDA’s recent work in digital health and beyond, as recently explained by Dr. Amy Abernathy, the principal deputy commissioner and acting CIO of the FDA, the agency has a rather broad plan to advance and indeed lead the use of data science in healthcare through these regulatory reforms. Last summer, FDA released a midyear report describing the agency’s progress in developing the PreCert Program for regulating “software as a medical device” (SaMD). Presumably toward the end of this year, FDA will release a final assessment of its pilot work for the year, and its proposals for the future. Based on Abernathy’s comments, FDA has very ambitious plans for the PreCert Program.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

But not everyone is enamored with what FDA is doing. On October 30, 2019, three US senators including presidential candidate Elizabeth Warren wrote FDA a follow-up letter (to their 2018 letter on the same topic) expressing concern over how: effectively the PreCert Program would protect patients, whether FDA had legal authority for the program, and how exactly FDA planned to make use of real-world evidence collected through the program.

So this seems like an appropriate time to discuss the criteria that stakeholders should use to evaluate the desirability of the PreCert Program. In this article, from that same data science perspective that FDA champions, I will review some of the key criteria that stakeholders should think about when they see the next iteration of the planned program.
Summary of FDA’s PreCert Program

The agency has been working to develop and then pilot the FDA Precertification Program for software since 2017. FDA’s most recent thinking on the program is reflected in a January 2019, 58-page “working model.” But it is still far from done. FDA has been spending 2019 testing some of the elements of the program on a few volunteer companies to see if the program features are administratively feasible. Presumably after this year, when FDA is done testing it, the agency will announce its future plans for the program.

At its heart, the program is about shifting regulatory focus from the software product to the company that develops the software product. Presently, typically a software developer that wants to get marketing approval from FDA would do so through two steps:

1. Voluntarily, under the so-called Q-Submission Program, engaging with FDA in a presubmission meeting to get feedback on what kinds of evidence the agency wants to see in a premarket submission; and

2. Submitting that submission.

Instead of those two steps, FDA would move to a four step process that begins with an initial focus on the company. Those four steps include:

1. An “excellence appraisal” to determine whether the company has a strong enough culture of quality to be admitted to the program.

2. A “review pathway determination” to decide which regulatory process and what kinds of evidence might be needed for a particular software submission. FDA proposes that this meeting be legally voluntary, but is not clear how the program would work without such a meeting.

3. The actual premarket review of the submission.

4. Ongoing collection and reporting to FDA of postmarket performance.

So basically steps one and four are added to the existing process, but the expectation is that the actual review — new step three — would be faster than the old step two because of the prior excellence appraisal and review pathway determination.
The Good in the Precert Program

FDA is thinking — in very creative ways — about how the agency will handle the significant growth in the development of SaMD type products in the future. Creativity is often difficult for a government agency simply because of law and politics, so for FDA to have the courage and vision to proactively pursue novel approaches is frankly wonderful.

Further, I love the idea of using data science, including algorithms, wherever they can be useful. In fact, this fall I enrolled as a graduate student to work on a Masters of Applied Data Science at the University of Michigan (at age 58, I may well be one of the oldest graduate students there.) There is no question that using sophisticated data collection and analysis techniques on FDA compliance issues can be useful.

Read more here

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Healthify Raises $16M to Integrate Health and Social ServicesHealthify Raises $16M to Integrate Health and Social Services
  • Lark, Healthpartners Team up to Provide AI-Powered Diabetes ManagementLark, Healthpartners Team up to Provide AI-Powered Diabetes Management
  • Thrive Global Acquires Boundless Mind, Neuroscience-Based Artificial Intelligence Company to Power Health and Productivity Behavior ChangeThrive Global Acquires Boundless Mind, Neuroscience-Based Artificial Intelligence Company to Power Health and Productivity Behavior Change
  • StartUp Health Adds 6 Digital Health Startups to its PortfolioStartUp Health Adds 6 Digital Health Startups to its Portfolio
  • Cerecor Closes Deal to Sell Pediatric PortfolioCerecor Closes Deal to Sell Pediatric Portfolio
  • Medicine Man To Acquire Cannabis Concentrate Processor; Shares Ahead 8%Medicine Man To Acquire Cannabis Concentrate Processor; Shares Ahead 8%
  • Tech-Enabled Insurance Startup Bright Health Plans Expansion with $635M Series DTech-Enabled Insurance Startup Bright Health Plans Expansion with $635M Series D
  • AMN Healthcare to Acquire Stratus VideoAMN Healthcare to Acquire Stratus Video

Trending This Week

  • EHR Vendor Cerner Eyes Developing a $1 Billion Data Business
  • Astonishing Growth in Global Pharmaceutical Market Which is Growing Exponentially with the Major Key Players in the Market Within the Forecast Period 2020-2027
  • Healthcare E-Commerce Market Demand, Insights and Forecast up to 2024
  • Starting the Year Dropping Cash – Two Companies Scooped Up This Week
  • Acquisitions of Biotech Startups Increased in 2020, With No Signs of Slowing Down
  • CareDx Agrees to Acquire Transchart and Expands EMR Connectivity to Over 90 Centersacquisition Will Build on CareDx’s Digital Capabilities and Continue Deepening the Moat with Transplant Centers

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications